Cargando...
EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma
PURPOSE: The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. Here we analyze a group of patients with GBM who received be...
Gardado en:
| Publicado en: | J Neurooncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6752204/ https://ncbi.nlm.nih.gov/pubmed/30680510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-019-03102-5 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|